Centessa Pharmaceuticals (CNTA) Invested Capital (2020 - 2026)

Centessa Pharmaceuticals (CNTA) has 7 years of Invested Capital data on file, last reported at $597.8 million in Q1 2026.

• Quarterly Invested Capital rose 20.64% year-over-year to $597.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $597.8 million (up 20.64% YoY) and the FY2025 annual result came in at $637.0 million, up 24.78% from the prior year.
• Invested Capital slipped to $597.8 million in Q1 2026 per CNTA's latest filing, from $637.0 million in the prior quarter.
• Across five years, Invested Capital topped out at $637.0 million in Q4 2025 and bottomed at $215.2 million in Q1 2024.
• The 5-year median for Invested Capital is $411.4 million (2025), against an average of $399.0 million.
• The widest annual swing landed in 2023, when Invested Capital sank 38.92%; it then jumped 130.29% in 2025.
• Tracing CNTA's Invested Capital over 5 years: stood at $336.2 million in 2022, then declined by 29.72% to $236.2 million in 2023, then surged by 116.08% to $510.5 million in 2024, then gained by 24.78% to $637.0 million in 2025, then decreased by 6.15% to $597.8 million in 2026.
• Per Business Quant, the three latest CNTA Invested Capital figures stand at $597.8 million (Q1 2026), $637.0 million (Q4 2025), and $411.4 million (Q3 2025).

Peer Comparison